Cover Image
市場調查報告書

流感A型的開發中產品分析

Influenza A Infections - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 232832
出版日期 內容資訊 英文 141 Pages
訂單完成後即時交付
價格
Back to Top
流感A型的開發中產品分析 Influenza A Infections - Pipeline Review, H2 2014
出版日期: 2014年09月30日 內容資訊: 英文 141 Pages
簡介

流感A型(H1N1)根據豬流感一起被招呼,感染了呼吸道的病毒發病。作為主要的症狀,發熱和呼吸疾病(咳嗽,嘶啞聲音,鼻涕·鼻塞),頭痛,肌肉痛,更加極度的倦怠感,及噁心,腹瀉等舉出(舉行)。在主要的治療方法裡(上)有抗病毒藥物等。

ユ⑦июリ⑦ЕA型(H1N1)ゾ豚ユ⑦июリ⑦Еシパ呼タホ、氣道ズ感染ウギヨユюЗズプベ發症ウネエ。主ス症狀シウサ、發熱ビ呼吸器疾患(オわ、ウマゎホ聲、鼻水・鼻ゴネベ)、頭痛、筋肉痛、更ズゾ極度ソ倦怠感ビ、吐わ氣、下痢スジゎ舉ァヘホネエ。主ス治療法ズゾ抗ヨユюЗ藥スジゎやベネエ。 當ярみЬザゾ、世界各國ザソユ⑦июリ⑦ЕA型治療用ソеユкьユ⑦製品ソ開發狀況ズコゆサ分析ウ、製品開發・上市ソ最新動向ビ、治驗ソ各段階ズやペ製品ソ一覽、主要企業ソк①иャユю、主ス藥劑ソ概要、最新ソ業界動向スジソ情報メれ屆んウネエ。

本報告提供全球各國治療A型流感用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

流感A型概要

治療藥的開發

  • 流感A型開發中產品:概要
  • 流感A型開發中產品:比較分析

各企業開發中的流感A型治療藥

大學/研究機關研究中的流感A型治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

流感A型治療藥:開發中的產品的一覽(各企業)

流感A型治療藥:研究中的產品一覽(大學/研究機關)別

流感A型治療藥的開發企業

  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Autoimmune Technologies, LLC
  • GlaxoSmithKline plc
  • Genentech, Inc.
  • Inovio Pharmaceuticals, Inc.
  • MedImmune, LLC
  • Crucell N.V.
  • Hemispherx Biopharma, Inc.
  • NanoViricides, Inc.
  • SIGA Technologies, Inc. (Inactive)
  • Vironova AB
  • CureVac GmbH
  • Chimerix, Inc.
  • Theraclone Sciences, Inc.
  • Immune Targeting Systems (ITS) Ltd.
  • Sinovac Biotech Ltd.
  • Microbiotix, Inc.
  • iBio, Inc.
  • Alios BioPharma, Inc.
  • Vivaldi Biosciences Inc.
  • Visterra, Inc.
  • ContraFect Corporation
  • Cure Lab, Inc.
  • Humabs BioMed SA
  • Microgen Scientific Industrial Company for Immunobiological Medicines

流感A型:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • FP-01
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • CR-8020
  • TCN-032
  • influenza vaccine (H5N2)
  • RG-7745
  • diridavumab
  • MEDI-550
  • influenza A vaccine (H7N7)
  • VIS-410
  • Live Attenuated Vaccine for H5N2 Influenza
  • GSK-3206641A
  • GSK-3206640A
  • Influenza A Vaccine [H7N9]
  • GSK-3277510A
  • GSK-3277509A
  • Influenza Vaccine [H7N9]
  • interferon alfa-n3
  • NVINF-2
  • Pandemic Influenza Vaccine (H1N1)
  • Flufirvitide-3
  • NVINF-1
  • Nucleozin
  • Small Molecule for Influenza A
  • ET-001
  • CR-8043
  • FI-6
  • DNA Vaccine for H7N9 Universal Influenza
  • Peptides for Influenza Infections
  • Gamma-Flu
  • Peptide to Agonize PAR-2 for Influenza A Infections
  • VH-244
  • CF-401
  • CF-402
  • Panavimab A
  • CLVax-1.0
  • Z-3G1
  • Small Molecules for Influenza A Infections
  • Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A Virus Infections
  • Small Molecule To Inhibit Hemagglutinin For Influenza A
  • Small Molecules to Block Influenza M2 Proton Channel for Influenza A Infections
  • AL-18
  • influenza vaccine (H7N9)
  • MBX-2329
  • MBX-2546
  • Recombinant Peptides for HIV-1 Infection and Influenza A Infections
  • Small Molecule for Influenza Virus
  • Small Molecules to Block M2 Channel for Influenza Infections
  • VX-353
  • Small Molecules to Block M2 Proton Channel for Influenza A Infections

流感A型治療藥:開發中產品的最新趨勢

流感A型治療藥:開發暫停的產品

流感A型治療藥:開發中止的產品

流感A型相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿(10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5459IDB

Summary

Global Markets Direct's, 'Influenza A Infections - Pipeline Review, H2 2014', provides an overview of the Influenza A Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Influenza A Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Influenza A Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Influenza A Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Influenza A Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A Infections Overview
  • Therapeutics Development
    • Pipeline Products for Influenza A Infections - Overview
    • Pipeline Products for Influenza A Infections - Comparative Analysis
  • Influenza A Infections - Therapeutics under Development by Companies
  • Influenza A Infections - Therapeutics under Investigation by Universities/Institutes
  • Influenza A Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Influenza A Infections - Products under Development by Companies
  • Influenza A Infections - Products under Investigation by Universities/Institutes
  • Influenza A Infections - Companies Involved in Therapeutics Development
    • Johnson & Johnson
    • Kyowa Hakko Kirin Co., Ltd.
    • Autoimmune Technologies, LLC
    • GlaxoSmithKline plc
    • Genentech, Inc.
    • Inovio Pharmaceuticals, Inc.
    • MedImmune, LLC
    • Crucell N.V.
    • Hemispherx Biopharma, Inc.
    • NanoViricides, Inc.
    • SIGA Technologies, Inc. (Inactive)
    • Vironova AB
    • CureVac GmbH
    • Chimerix, Inc.
    • Theraclone Sciences, Inc.
    • Immune Targeting Systems (ITS) Ltd.
    • Sinovac Biotech Ltd.
    • Microbiotix, Inc.
    • iBio, Inc.
    • Alios BioPharma, Inc.
    • Vivaldi Biosciences Inc.
    • Visterra, Inc.
    • ContraFect Corporation
    • Cure Lab, Inc.
    • Humabs BioMed SA
    • Microgen Scientific Industrial Company for Immunobiological Medicines
  • Influenza A Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • FP-01 - Drug Profile
    • CR-8020 - Drug Profile
    • TCN-032 - Drug Profile
    • influenza vaccine (H5N2) - Drug Profile
    • RG-7745 - Drug Profile
    • diridavumab - Drug Profile
    • MEDI-550 - Drug Profile
    • influenza A vaccine (H7N7) - Drug Profile
    • VIS-410 - Drug Profile
    • Live Attenuated Vaccine for H5N2 Influenza - Drug Profile
    • GSK-3206641A - Drug Profile
    • GSK-3206640A - Drug Profile
    • Influenza A Vaccine [H7N9] - Drug Profile
    • GSK-3277510A - Drug Profile
    • GSK-3277509A - Drug Profile
    • Influenza Vaccine [H7N9] - Drug Profile
    • interferon alfa-n3 - Drug Profile
    • NVINF-2 - Drug Profile
    • Pandemic Influenza Vaccine (H1N1) - Drug Profile
    • Flufirvitide-3 - Drug Profile
    • NVINF-1 - Drug Profile
    • Nucleozin - Drug Profile
    • Small Molecule for Influenza A - Drug Profile
    • ET-001 - Drug Profile
    • CR-8043 - Drug Profile
    • FI-6 - Drug Profile
    • DNA Vaccine for H7N9 Universal Influenza - Drug Profile
    • Peptides for Influenza Infections - Drug Profile
    • Gamma-Flu - Drug Profile
    • Peptide to Agonize PAR-2 for Influenza A Infections - Drug Profile
    • VH-244 - Drug Profile
    • CF-401 - Drug Profile
    • CF-402 - Drug Profile
    • Panavimab A - Drug Profile
    • CLVax-1.0 - Drug Profile
    • Z-3G1 - Drug Profile
    • Small Molecules for Influenza A Infections - Drug Profile
    • Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A Virus Infections - Drug Profile
    • Small Molecule To Inhibit Hemagglutinin For Influenza A - Drug Profile
    • Small Molecules to Block Influenza M2 Proton Channel for Influenza A Infections - Drug Profile
    • AL-18 - Drug Profile
    • influenza vaccine (H7N9) - Drug Profile
    • MBX-2329 - Drug Profile
    • MBX-2546 - Drug Profile
    • Recombinant Peptides for HIV-1 Infection and Influenza A Infections - Drug Profile
    • Small Molecule for Influenza Virus - Drug Profile
    • Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile
    • VX-353 - Drug Profile
    • Small Molecules to Block M2 Proton Channel for Influenza A Infections - Drug Profile
  • Influenza A Infections - Recent Pipeline Updates
  • Influenza A Infections - Dormant Projects
  • Influenza A Infections - Discontinued Products
  • Influenza A Infections - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Influenza A Infections, H2 2014
  • Number of Products under Development for Influenza A Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Development by Companies, H2 2014 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Development by Companies, H2 2014 (Contd..1)
  • Products under Development by Companies, H2 2014 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2014
  • Influenza A Infections - Pipeline by Johnson & Johnson, H2 2014
  • Influenza A Infections - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014
  • Influenza A Infections - Pipeline by Autoimmune Technologies, LLC, H2 2014
  • Influenza A Infections - Pipeline by GlaxoSmithKline plc, H2 2014
  • Influenza A Infections - Pipeline by Genentech, Inc., H2 2014
  • Influenza A Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014
  • Influenza A Infections - Pipeline by MedImmune, LLC, H2 2014
  • Influenza A Infections - Pipeline by Crucell N.V., H2 2014
  • Influenza A Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2014
  • Influenza A Infections - Pipeline by NanoViricides, Inc., H2 2014
  • Influenza A Infections - Pipeline by SIGA Technologies, Inc. (Inactive), H2 2014
  • Influenza A Infections - Pipeline by Vironova AB, H2 2014
  • Influenza A Infections - Pipeline by CureVac GmbH, H2 2014
  • Influenza A Infections - Pipeline by Chimerix, Inc., H2 2014
  • Influenza A Infections - Pipeline by Theraclone Sciences, Inc., H2 2014
  • Influenza A Infections - Pipeline by Immune Targeting Systems (ITS) Ltd., H2 2014
  • Influenza A Infections - Pipeline by Sinovac Biotech Ltd., H2 2014
  • Influenza A Infections - Pipeline by Microbiotix, Inc., H2 2014
  • Influenza A Infections - Pipeline by iBio, Inc., H2 2014
  • Influenza A Infections - Pipeline by Alios BioPharma, Inc., H2 2014
  • Influenza A Infections - Pipeline by Vivaldi Biosciences Inc., H2 2014
  • Influenza A Infections - Pipeline by Visterra, Inc., H2 2014
  • Influenza A Infections - Pipeline by ContraFect Corporation, H2 2014
  • Influenza A Infections - Pipeline by Cure Lab, Inc., H2 2014
  • Influenza A Infections - Pipeline by Humabs BioMed SA, H2 2014
  • Influenza A Infections - Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Influenza A Infections Therapeutics - Recent Pipeline Updates, H2 2014
  • Influenza A Infections - Dormant Projects, H2 2014
  • Influenza A Infections - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Influenza A Infections, H2 2014
  • Number of Products under Development for Influenza A Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top